Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors: The Japan Marrow Donor Program

Hideki Muramatsu, Seiji Kojima, Ayami Yoshimi, Yoshiko Atsuta, Koji Kato, Yoshihisa Nagatoshi, Masami Inoue, Kazutoshi Koike, Takakazu Kawase, Masaki Ito, Hidemitsu Kurosawa, Akihiko Tanizawa, Chikako Tono, Kazuko Hamamoto, Noriko Hotta, Akihiro Watanabe, Yasuo Morishima, Keisei Kawa, Hiroyuki Shimada

    Research output: Contribution to journalArticle

    24 Citations (Scopus)

    Abstract

    Because of a small number of patients, only a few studies have addressed the outcome of bone marrow transplantation (BMT) in children with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), who receive graft from a volunteer-unrelated donor (VUD), especially after practical application of imatinib mesylate. The outcomes of BMT from a VUD in 125 children with Ph+ CML were retrospectively reviewed. Patients were identified through the Japan Marrow Donor Program as having undergone BMT between 1993 and 2005 and were aged 1-19 years at the time of transplant (median age, 14 years). The probabilities of 5-year overall survival (OS) and leukemia-free survival (LFS) were 59.3% and 55.5%, respectively. Multivariate analysis identified the following unfavorable survival factors: infused total nucleated cell dose < 314 × 106 /kg (relative risk [RR] = 2.43; 95% confidence interval [CI] = 1.33-4.44; P = .004), advanced phase (RR = 2.43; 95% CI = 1.37-4.31; P = .004), and no major cytogenetic response (MCyR) at the time of BMT (RR = 6.55; 95% CI = 1.98-21.6; P = .002). Of the 17 patients treated with imatinib, 15 (88%) achieved MCyR at the time of BMT, and this group had an excellent 5-year OS of 81.9%. Disease phase, infused total nucleated cell dose, and cytogenetic response were independent risk factors for survival of unrelated BMT. These findings provide important information for assessing the indications for and improving outcome in unrelated BMT for the treatment of pediatric CML.

    Original languageEnglish
    Pages (from-to)231-238
    Number of pages8
    JournalBiology of Blood and Marrow Transplantation
    Volume16
    Issue number2
    DOIs
    Publication statusPublished - Feb 1 2010

    Fingerprint

    Unrelated Donors
    Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    Bone Marrow Transplantation
    Japan
    Bone Marrow
    Tissue Donors
    Transplants
    Survival
    Cytogenetics
    Confidence Intervals
    Volunteers
    Philadelphia Chromosome
    Leukemia
    Multivariate Analysis
    Pediatrics

    All Science Journal Classification (ASJC) codes

    • Hematology
    • Transplantation

    Cite this

    Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors : The Japan Marrow Donor Program. / Muramatsu, Hideki; Kojima, Seiji; Yoshimi, Ayami; Atsuta, Yoshiko; Kato, Koji; Nagatoshi, Yoshihisa; Inoue, Masami; Koike, Kazutoshi; Kawase, Takakazu; Ito, Masaki; Kurosawa, Hidemitsu; Tanizawa, Akihiko; Tono, Chikako; Hamamoto, Kazuko; Hotta, Noriko; Watanabe, Akihiro; Morishima, Yasuo; Kawa, Keisei; Shimada, Hiroyuki.

    In: Biology of Blood and Marrow Transplantation, Vol. 16, No. 2, 01.02.2010, p. 231-238.

    Research output: Contribution to journalArticle

    Muramatsu, H, Kojima, S, Yoshimi, A, Atsuta, Y, Kato, K, Nagatoshi, Y, Inoue, M, Koike, K, Kawase, T, Ito, M, Kurosawa, H, Tanizawa, A, Tono, C, Hamamoto, K, Hotta, N, Watanabe, A, Morishima, Y, Kawa, K & Shimada, H 2010, 'Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors: The Japan Marrow Donor Program', Biology of Blood and Marrow Transplantation, vol. 16, no. 2, pp. 231-238. https://doi.org/10.1016/j.bbmt.2009.09.022
    Muramatsu, Hideki ; Kojima, Seiji ; Yoshimi, Ayami ; Atsuta, Yoshiko ; Kato, Koji ; Nagatoshi, Yoshihisa ; Inoue, Masami ; Koike, Kazutoshi ; Kawase, Takakazu ; Ito, Masaki ; Kurosawa, Hidemitsu ; Tanizawa, Akihiko ; Tono, Chikako ; Hamamoto, Kazuko ; Hotta, Noriko ; Watanabe, Akihiro ; Morishima, Yasuo ; Kawa, Keisei ; Shimada, Hiroyuki. / Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors : The Japan Marrow Donor Program. In: Biology of Blood and Marrow Transplantation. 2010 ; Vol. 16, No. 2. pp. 231-238.
    @article{c985990fcc9546fd94e0c5e5ec394866,
    title = "Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors: The Japan Marrow Donor Program",
    abstract = "Because of a small number of patients, only a few studies have addressed the outcome of bone marrow transplantation (BMT) in children with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), who receive graft from a volunteer-unrelated donor (VUD), especially after practical application of imatinib mesylate. The outcomes of BMT from a VUD in 125 children with Ph+ CML were retrospectively reviewed. Patients were identified through the Japan Marrow Donor Program as having undergone BMT between 1993 and 2005 and were aged 1-19 years at the time of transplant (median age, 14 years). The probabilities of 5-year overall survival (OS) and leukemia-free survival (LFS) were 59.3{\%} and 55.5{\%}, respectively. Multivariate analysis identified the following unfavorable survival factors: infused total nucleated cell dose < 314 × 106 /kg (relative risk [RR] = 2.43; 95{\%} confidence interval [CI] = 1.33-4.44; P = .004), advanced phase (RR = 2.43; 95{\%} CI = 1.37-4.31; P = .004), and no major cytogenetic response (MCyR) at the time of BMT (RR = 6.55; 95{\%} CI = 1.98-21.6; P = .002). Of the 17 patients treated with imatinib, 15 (88{\%}) achieved MCyR at the time of BMT, and this group had an excellent 5-year OS of 81.9{\%}. Disease phase, infused total nucleated cell dose, and cytogenetic response were independent risk factors for survival of unrelated BMT. These findings provide important information for assessing the indications for and improving outcome in unrelated BMT for the treatment of pediatric CML.",
    author = "Hideki Muramatsu and Seiji Kojima and Ayami Yoshimi and Yoshiko Atsuta and Koji Kato and Yoshihisa Nagatoshi and Masami Inoue and Kazutoshi Koike and Takakazu Kawase and Masaki Ito and Hidemitsu Kurosawa and Akihiko Tanizawa and Chikako Tono and Kazuko Hamamoto and Noriko Hotta and Akihiro Watanabe and Yasuo Morishima and Keisei Kawa and Hiroyuki Shimada",
    year = "2010",
    month = "2",
    day = "1",
    doi = "10.1016/j.bbmt.2009.09.022",
    language = "English",
    volume = "16",
    pages = "231--238",
    journal = "Biology of Blood and Marrow Transplantation",
    issn = "1083-8791",
    publisher = "Elsevier Inc.",
    number = "2",

    }

    TY - JOUR

    T1 - Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors

    T2 - The Japan Marrow Donor Program

    AU - Muramatsu, Hideki

    AU - Kojima, Seiji

    AU - Yoshimi, Ayami

    AU - Atsuta, Yoshiko

    AU - Kato, Koji

    AU - Nagatoshi, Yoshihisa

    AU - Inoue, Masami

    AU - Koike, Kazutoshi

    AU - Kawase, Takakazu

    AU - Ito, Masaki

    AU - Kurosawa, Hidemitsu

    AU - Tanizawa, Akihiko

    AU - Tono, Chikako

    AU - Hamamoto, Kazuko

    AU - Hotta, Noriko

    AU - Watanabe, Akihiro

    AU - Morishima, Yasuo

    AU - Kawa, Keisei

    AU - Shimada, Hiroyuki

    PY - 2010/2/1

    Y1 - 2010/2/1

    N2 - Because of a small number of patients, only a few studies have addressed the outcome of bone marrow transplantation (BMT) in children with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), who receive graft from a volunteer-unrelated donor (VUD), especially after practical application of imatinib mesylate. The outcomes of BMT from a VUD in 125 children with Ph+ CML were retrospectively reviewed. Patients were identified through the Japan Marrow Donor Program as having undergone BMT between 1993 and 2005 and were aged 1-19 years at the time of transplant (median age, 14 years). The probabilities of 5-year overall survival (OS) and leukemia-free survival (LFS) were 59.3% and 55.5%, respectively. Multivariate analysis identified the following unfavorable survival factors: infused total nucleated cell dose < 314 × 106 /kg (relative risk [RR] = 2.43; 95% confidence interval [CI] = 1.33-4.44; P = .004), advanced phase (RR = 2.43; 95% CI = 1.37-4.31; P = .004), and no major cytogenetic response (MCyR) at the time of BMT (RR = 6.55; 95% CI = 1.98-21.6; P = .002). Of the 17 patients treated with imatinib, 15 (88%) achieved MCyR at the time of BMT, and this group had an excellent 5-year OS of 81.9%. Disease phase, infused total nucleated cell dose, and cytogenetic response were independent risk factors for survival of unrelated BMT. These findings provide important information for assessing the indications for and improving outcome in unrelated BMT for the treatment of pediatric CML.

    AB - Because of a small number of patients, only a few studies have addressed the outcome of bone marrow transplantation (BMT) in children with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), who receive graft from a volunteer-unrelated donor (VUD), especially after practical application of imatinib mesylate. The outcomes of BMT from a VUD in 125 children with Ph+ CML were retrospectively reviewed. Patients were identified through the Japan Marrow Donor Program as having undergone BMT between 1993 and 2005 and were aged 1-19 years at the time of transplant (median age, 14 years). The probabilities of 5-year overall survival (OS) and leukemia-free survival (LFS) were 59.3% and 55.5%, respectively. Multivariate analysis identified the following unfavorable survival factors: infused total nucleated cell dose < 314 × 106 /kg (relative risk [RR] = 2.43; 95% confidence interval [CI] = 1.33-4.44; P = .004), advanced phase (RR = 2.43; 95% CI = 1.37-4.31; P = .004), and no major cytogenetic response (MCyR) at the time of BMT (RR = 6.55; 95% CI = 1.98-21.6; P = .002). Of the 17 patients treated with imatinib, 15 (88%) achieved MCyR at the time of BMT, and this group had an excellent 5-year OS of 81.9%. Disease phase, infused total nucleated cell dose, and cytogenetic response were independent risk factors for survival of unrelated BMT. These findings provide important information for assessing the indications for and improving outcome in unrelated BMT for the treatment of pediatric CML.

    UR - http://www.scopus.com/inward/record.url?scp=75149193809&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=75149193809&partnerID=8YFLogxK

    U2 - 10.1016/j.bbmt.2009.09.022

    DO - 10.1016/j.bbmt.2009.09.022

    M3 - Article

    C2 - 19800016

    AN - SCOPUS:75149193809

    VL - 16

    SP - 231

    EP - 238

    JO - Biology of Blood and Marrow Transplantation

    JF - Biology of Blood and Marrow Transplantation

    SN - 1083-8791

    IS - 2

    ER -